This site is intended for US healthcare professionals.
Achieving Later-Line Benefits
Research is pursuing effective and tolerable therapy, potentially offering hope for patients with rrRCC15,16
Because treatment decisions take into account safety and tolerability, including the impact of comorbidities and prior therapies,8 the development of well-tolerated treatment options is essential to continuing care
Delaying symptoms is an essential goal: progressing symptomatic disease imposes a significant burden of complications, pain, and physical limitations, negatively impacting quality of life17
As RCC advances, quality of life implications become increasingly important18
Finding effective and tolerable treatment is especially critical in later-line RCC since AEs continue to pose a clinical challenge and poor performance status can be a barrier to receiving therapy13,19